SEC Form 4 · accession 0001104659-26-093140
Braveheart Bio, Inc. · BRVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Aug 7, 2026
Accepted (ET)
Aug 10, 2026 · 10:03 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002131524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 7, 2026 | C | 7,420,091 | — | A | 7,420,091 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-voting Series A preferred stockF1 | — | Aug 7, 2026 | C | 32,500,000 | D | — | — | Common Stock | 7,420,091 | 0 | D |
Explanation of responses
- F1The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.